Benign Prostatic Hyperplasia Surgical Treatment Market Size, Share, & Industry Analysis Report By Type [Transurethral Resection of Prostate (TURP), Prostatic Urethral Lift], By End User, By Region – Market Forecast, 2025–2034
Description
The benign prostatic hyperplasia surgical treatment market size is expected to reach USD 3,412.57 million by 2034, according to a new study by Polaris Market Research. The report “Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift], By End User, By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.
The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.
Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights
In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.
Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.
The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.
Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.
A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.
Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:
By Type Outlook (Revenue, USD Million, 2020–2034)
Transurethral Resection of Prostate (TURP)
Prostatic Urethral Lift
Water Vapor Therapy
Laser Therapy
Aquablation Therapy
Transurethral Microwave Thermotherapy (TUMT)
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgery Centers and Clinics
Homecare Settings
By Regional Outlook (Revenue, USD Million, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.
The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.
Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights
In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.
Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.
The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.
Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.
A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.
Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:
By Type Outlook (Revenue, USD Million, 2020–2034)
Transurethral Resection of Prostate (TURP)
Prostatic Urethral Lift
Water Vapor Therapy
Laser Therapy
Aquablation Therapy
Transurethral Microwave Thermotherapy (TUMT)
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgery Centers and Clinics
Homecare Settings
By Regional Outlook (Revenue, USD Million, 2020–2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
129 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
